![High-flow nasal oxygenation or standard oxygenation for gastrointestinal endoscopy with sedation in patients at risk of hypoxaemia: a multicentre randomised controlled trial (ODEPHI trial) - British Journal of Anaesthesia High-flow nasal oxygenation or standard oxygenation for gastrointestinal endoscopy with sedation in patients at risk of hypoxaemia: a multicentre randomised controlled trial (ODEPHI trial) - British Journal of Anaesthesia](https://www.bjanaesthesia.org.uk/cms/asset/0b10fb49-b934-4d54-92b8-d934c672e7c1/gr1.jpg)
High-flow nasal oxygenation or standard oxygenation for gastrointestinal endoscopy with sedation in patients at risk of hypoxaemia: a multicentre randomised controlled trial (ODEPHI trial) - British Journal of Anaesthesia
![Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomised trial in seven low-income and middle-income countries - The Lancet Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomised trial in seven low-income and middle-income countries - The Lancet](https://www.thelancet.com/cms/attachment/3d373b40-4e1d-4697-9242-a24d5dbeac11/gr1.jpg)
Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomised trial in seven low-income and middle-income countries - The Lancet
![Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/1ed2d6f1-ced6-4ed1-a7f2-bd3bf926b68e/gr1.jpg)
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/08c720cc-e47c-4f66-8a74-41a09282f867/gr1.gif)
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology
![Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials - The Lancet Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials - The Lancet](https://www.thelancet.com/cms/attachment/6d79da4c-93a3-46de-af9b-484ab1913b53/gr1.jpg)
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials - The Lancet
![Overview of Secondary Nucleation: From Fundamentals to Application | Industrial & Engineering Chemistry Research Overview of Secondary Nucleation: From Fundamentals to Application | Industrial & Engineering Chemistry Research](https://pubs.acs.org/cms/10.1021/acs.iecr.0c03304/asset/images/large/ie0c03304_0011.jpeg)